Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Q3: We Expect Enox PI to Hold, Generic Copaxone Trial Ruling in Mid-2012

Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $22.00.

Canaccord analyst, Ritu Baral, said, "Preliminary injunction (PI) stabilizes m-enox revenues near term. We think m-enox revenue will decline Q4/11 on authorized generic (AG) launch but stabilize with the PI against Amphastar. We think the generic Copaxone suit will resolve in MNTA’s favor in mid-2012."

For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.

Shares of Momenta Pharmaceuticals closed at $14.34 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Deere (DE) PT Raised to $585 at JPMorgan
• DA Davidson Starts Everus (ECG) at Buy